Aerocrine Release: Mississippi’s Medicaid Program Adds Coverage for Aerocrine’s FeNO Testing in Asthma Management Following a New ATS Guideline

SOLNA, Sweden--(BUSINESS WIRE)--Regulatory News:

Aerocrine AB (OMX Nordic Exchange: AERO) today announced that Mississippi’s Medicaid program adds FeNO reimbursement coverage, making 29 states plus the District of Columbia covering this cost-effective test for managing asthma.